Login to Your Account

Go early, go big, go global: Aslan licenses preclinical MAb for asthma

By Shannon Ellis
Staff Writer

Wednesday, May 14, 2014

SHANGHAI – Aslan Pharmaceuticals Pte Ltd. signed an agreement for global rights with CSL Ltd. to develop an anti-IL13 receptor monoclonal antibody, CSL334, for severe to moderate asthma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription